Syndax anticipates Revuforj could exceed $2B in U.S. peak annual net revenue as post-transplant maintenance builds (NASDAQ:SNDX)
· seekingalpha.com
Syndax Q3 2026 earnings: Revuforj and Niktimvo drove strong revenue growth, with 2027 catalysts ahead.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...